Citation Impact
Citing Papers
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
2009
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
2008
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
2010
Suppression of Aging in Mice by the Hormone Klotho
2005 StandoutScience
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants
2019 StandoutScienceNobel
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
2002 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Signalling and survival pathways in multiple myeloma
2006
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Distinct fibroblast lineages determine dermal architecture in skin development and repair
2013 StandoutNature
Homocysteine and vascular disease
1999 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
2009
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Expression of Interleukin-6 (IL-6) and IL-6 receptor mRNA in human bone samples from pre- and postmenopausal women
2002
Cancer to bone: a fatal attraction
2011 Standout
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future
2012
Meta-analysis of Genetic Studies in Ischemic Stroke
2004
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms
2000
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on Bone
2009
Abdominal aortic aneurysm
2005 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis
2016
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
AID Is Required for c-myc/IgH Chromosome Translocations In Vivo
2004 StandoutNobel
Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.
1997
Pathogenesis of myeloma bone disease
2008
Osteoporosis: now and the future
2011 Standout
Homocysteine and cardiovascular disease: cause or effect?
2000
Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation
2008
Translational control in cancer
2010
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Two RNA-binding motifs in eIF3 direct HCV IRES-dependent translation
2013 StandoutNobel
PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses
2007 Standout
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies
2003
WNT signalling in the immune system: WNT is spreading its wings
2008
Integrin α4β1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion
2004
Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development
2010
Graves' Ophthalmopathy
2010 Standout
Obesity, haemostasis and the fibrinolytic system
2002
Homocysteine and Risk of Ischemic Heart Disease and Stroke
2002 Standout
Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment
2009
A comprehensive review of genetic association studies
2002
Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltrates
2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Systemic amyloidosis
2015 Standout
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Osteoclast differentiation and activation
2003 StandoutNature
Elevated C-Reactive Protein Levels in Overweight and Obese Adults
1999 Standout
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Pathogenesis and treatment of renal failure in multiple myeloma
2008
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
2014
Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk
2004
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study
2007
Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke
2004
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Bone metastasis: the importance of the neighbourhood
2016
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Treatment of Multiple Myeloma: A Comprehensive Review
2009
Cancer-related inflammation
2008 StandoutNature
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
2012
CXCR3 ligands in disease and therapy
2014
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
Neoplastic development in plasma cells
2003
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
2008
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Hyperhomocysteinemia, Atherosclerosis and Thrombosis
1999
Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke
2002
CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells
2007
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
2009
Relative Overexpression of Macrophage-Derived Cytokines in Orbital Adipose Tissue from Patients with Graves’ Ophthalmopathy
2003
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
2012
Factor V Leiden, Prothrombin Gene G20210A Variant, and Methylenetetrahydrofolate Reductase C677T Genotype in Young Adults With Ischemic Stroke
2001
Hyperhomocysteinemia and Other Inherited Prothrombotic Conditions in Young Adults With a History of Ischemic Stroke
2002
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
2010
Targeting the bone marrow microenvironment in multiple myeloma
2014
Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD
2007
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
2009
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
2008
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
Meta-Analysis of Factor V Leiden and Ischemic Stroke in Young Adults
2010
Multiple Myeloma
2010
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Testing for Inherited Thrombophilias in Arterial Stroke
2010
Electrochemiluminescence (ECL)
2004 Standout
Inherited Thrombophilic Disorders in Young Adults With Ischemic Stroke and Patent Foramen Ovale
2003
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss
2017
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
2014
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
2004
Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses
2002
Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production
1998
Primary Prevention of Ischemic Stroke
2001
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
2003
Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO
2003
Association Between a Functional Variant of the KLOTHO Gene and High-Density Lipoprotein Cholesterol, Blood Pressure, Stroke, and Longevity
2005
Geometric cues for directing the differentiation of mesenchymal stem cells
2010 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
The Pathophysiologic Roles of Interleukin-6 in Human Disease
1998
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Functional reconstitution of human eukaryotic translation initiation factor 3 (eIF3)
2011 StandoutNobel
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
2006
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
2006 Standout
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
2009
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
2005
Pathophysiology of Graves’ Ophthalmopathy: The Cycle of Disease
2003
Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1
2005
Atomically Precise Clusters of Noble Metals: Emerging Link between Atoms and Nanoparticles
2017 Standout
Works of Nicola Giuliani being referenced
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules
2012
Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients
2005
New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL)
2004
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis
2004
Angiogenesis and Multiple Myeloma
2011
Impact of XIAP protein levels on the survival of myeloma cells
2008
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking
2000
Bisphosphonates Stimulate Formation of Osteoblast Precursors and Mineralized Nodules in Murine and Human Bone Marrow Cultures In Vitro and Promote Early Osteoblastogenesis in Young and Aged Mice In Vivo
1998
Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes
2001
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction
2013
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
2006
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
2005
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival.
2006
A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide
2011
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
2010
PAI-1 Plasma Levels in a General Population Without Clinical Evidence of Atherosclerosis
1998
The Methylenetetrahydrofolate Reductase TT677 Genotype Is Associated with Venous Thrombosis Independently of the Coexistence of the FV Leiden and the Prothrombin
1998
Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
1996
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
2005
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment
2001
Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiontensin Converting Enzyme (ACE) Genes
1997
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
2009
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
2007
The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease
1998
Inherited Prothrombotic Conditions and Premature Ischemic Stroke
1999
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network
2007
Deletion Polymorphism in the Angiotensin-Converting Enzyme Gene in Patients With a History of Ischemic Stroke
1996
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways
2008
Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment
2007